From 2018 to 2019, around 3,110 individuals in the United States died due to binge eating disorder, while another 3,430 died due to other specified feeding and eating disorders. This statistic illustrates the total number of deaths in the United States due to eating disorders from 2018 to 2019, by condition.

This statistic depicts the number of direct deaths from eating disorders in the U.S. from 1990 to 2019. According to the data the yearly number of deaths has increased from 22 in 1990 to 41 in 2019.

From 2018 to 2019, around 340 U.S. females aged 30 to 39 years died due to anorexia nervosa, while another 380 females in the same age group died due to other specified feeding and eating disorders. This statistic illustrates the number of female deaths in the United States due to eating disorders from 2018 to 2019, by age and condition.

From 2018 to 2019, around 390 U.S. males aged 20 to 29 years died due to anorexia nervosa, while around another 150 males in the same age group died due to other specified feeding and eating disorders. This statistic illustrates the number of male deaths in the United States due to eating disorders from 2018 to 2019, by age and condition.

This statistic depicts the number of direct deaths from eating disorders worldwide from 1990 to 2019. According to the data, in 2019 there were 318 direct deaths from eating disorders worldwide.

The number of deaths caused by anorexia in Spain was overall higher among women than among men during the period analyzed. In 2022, the number of deaths due to this condition amounted to ****, affecting **** women and no men. In 2013, there were no reported deaths related to anorexia, an eating disorder featured by low body weight, fear of gaining weight, food restriction, and body image disturbance.

Dataset

This dataset was created by valcho valev

Contents

Abstract Background Severe and enduring anorexia nervosa (SE-AN), is a serious and persistent illness, despite ‘state of the art’ treatment. Criteria have been theoretically proposed, but not tested, and may not adequately capture illness complexity, which potentially inhibits treatment refinements. The clinical reality of death as an outcome for some people who experience SE-AN (1 in 20) and broadening access to voluntary assisted dying, further complicates the field, which is undeveloped regarding more fundamental concepts such as nosology, treatment, recovery definitions and alternative conceptualisations of SE-AN. The present paper is in response to this and aims to build upon qualitative literature to enhance phenomenological understandings of fatal SE-AN. Method A published book, being the legacy of a 32-year-old professional artist offers a rich account of a life lived with AN, for 18 years with continuous treatment. A polysemous narrative via the interrelationship between the languages of the artist’s words and visual art is translated via interpretative phenomenological analysis (IPA), offering rich insight into the SE-AN experience. Findings The process of analysis induced three superordinate themes (1) Disappearing Self (2) Dialectical Dilemma (3) Death and Dying: Finding Meaning. Two cross cutting themes traversed these themes: (a) Colour and (b) Shifting Hope, where the former produced a visual representation via the ‘SE-AN Kaleidoscope’. Collectively the themes produce a concept of SE-AN, grounded in the data and depicted visually through the artist’s paintings. Conclusions The picture of SE-AN revealed in the analysis extends upon conceptualisations of SE-AN, highlighting key processes which are thus far under explored. These factors are implicated in illness persistence eliciting opportunities for further research testing including diagnostic considerations and treatment directions. In SE-AN, distorted body image extends to a global distortion in the perception of self. Additional criteria for the severe and enduring stages of illness related to (1) self and identity processes (2) measures of ‘global impoverishment’ across life domains are proposed for consideration in the future testing of putative defining features of SE-AN.

Abstract Background Understanding of the epidemiology and health burden of eating disorders has progressed significantly in the last 2 decades. It was considered one of seven key areas to inform the Australian Government commissioned National Eating Disorder Research and Translation Strategy 2021–2031, as emerging research had highlighted a rise in eating disorder prevalence and worsening burden-of-illness. The aim of this review was to better understand the global epidemiology and impact of eating disorders to inform policy decision-making. Methods Using a systematic Rapid Review methodology, ScienceDirect, PubMed and Medline (Ovid) were searched for peer-reviewed studies published between 2009 and 2021. Clear inclusion criteria were developed in consultation with experts in the field. Purposive sampling of literature was conducted, which predominately focused on higher-level evidence (meta-analyses, systematic reviews, and large epidemiological studies), synthesised, and narratively analysed. Results 135 studies were deemed eligible for inclusion in this review (N = 1324). Prevalence estimates varied. Global Lifetime prevalence of any eating disorder ranged from 0.74 to 2.2% in males, and 2.58–8.4% in females. Australian 3-month point-prevalence of broadly defined disorders was around 16% in females. Eating disorders appeared more prevalent in young people and adolescents, particularly females (in Australia: eating disorders ~ 22.2%; disordered eating ~ 25.7%). Limited evidence was found on sex, sexuality and gender diverse (LGBTQI +) individuals, particularly males, who had a six-fold increase in prevalence compared to the general male population, with increased illness impact. Similarly, limited evidence on First Australian’s (Aboriginal and Torres Strait Islander) suggests prevalence rates similar to non-Indigenous Australians. No prevalence studies were identified specifically assessing culturally and linguistically diverse populations. Global disease burden of any eating disorder was 43.4 age-standardised disability-adjusted-life-years per 100,000; increasing by 9.4% between 2007 and 2017. Australian’s total economic cost was estimated at $84 billion from years-of-life lost due to disability and death, and annual lost earnings ~ $1.646 billion.” Conclusions There is no doubt that eating disorder prevalence and impact are on the rise, particularly in at-risk and understudied populations. Much of the evidence came from female-only samples, and Western, high-income countries which more readily have access to specialised services. Future research should examine more representative samples. There is an urgent need for more refined epidemiological methods to better understand these complex illnesses over time, to guide health policy and development-of-care.

From 1990 to 2017, the prevalence of eating disorders worldwide among adults aged 30 to 34 years increased from .44 percent to .51 percent. This statistic illustrates the prevalence of eating disorders worldwide from 1990 to 2017, by age.

Cancer Anorexia-Cachexia Syndrome Drug Market Outlook

The global market size for Cancer Anorexia-Cachexia Syndrome (CACS) drugs was valued at USD 2.5 billion in 2023 and is projected to reach USD 4.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 6.9% during the forecast period. This growth is driven by the increasing prevalence of cancer and heightened awareness regarding cancer-related complications, including anorexia-cachexia syndrome.

One of the primary growth factors for this market is the rising incidence of cancer worldwide. According to the World Health Organization (WHO), cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. As cancer cases continue to rise, the prevalence of CACS—a complex metabolic syndrome characterized by severe weight loss, muscle atrophy, and anorexia—also increases. This has led to a heightened demand for effective drugs that can manage and alleviate the symptoms of CACS, thereby driving market growth.

Another major growth driver is the increasing research and development activities focused on understanding the pathophysiology of CACS and developing targeted therapies. Biopharmaceutical companies and research institutions are investing heavily in clinical trials to evaluate the efficacy of novel drug candidates. Advances in biotechnology and molecular biology are enabling the development of more effective and personalized treatments for CACS, which is expected to fuel market expansion.

Additionally, the growing awareness among healthcare professionals and patients about the importance of early diagnosis and treatment of CACS is contributing to market growth. Various educational campaigns, conferences, and seminars are being organized to disseminate information about CACS and the available treatment options. This increased awareness is likely to result in higher diagnosis rates and subsequently, a higher demand for CACS drugs.

In terms of regional outlook, North America currently holds the largest share of the CACS drug market, primarily due to the high prevalence of cancer, advanced healthcare infrastructure, and significant investment in research and development. Europe follows closely, driven by similar factors. However, the Asia Pacific region is expected to witness the fastest growth during the forecast period, owing to improving healthcare facilities, increasing cancer incidence, and growing awareness about CACS in emerging economies like China and India. Latin America and the Middle East & Africa regions are also anticipated to experience moderate growth due to rising healthcare investments and cancer awareness initiatives.

Drug Type Analysis

The Cancer Anorexia-Cachexia Syndrome drug market can be segmented by drug type into progestogens, corticosteroids, combination therapies, and others. Progestogens, such as megestrol acetate, are widely used due to their effectiveness in improving appetite and weight gain in CACS patients. These drugs work by stimulating appetite and promoting fat storage, making them a popular choice among healthcare providers. The widespread use of progestogens is a significant contributor to their substantial market share.

Corticosteroids, like dexamethasone and prednisone, are another key segment. These drugs are commonly prescribed to manage inflammation and improve appetite in CACS patients. Corticosteroids are known for their rapid onset of action, which makes them useful in palliative care settings. However, their long-term use is associated with side effects, which may limit their market growth to some extent. Nonetheless, the demand for corticosteroids remains robust due to their efficacy in symptom management.

Combination therapies, which involve the use of two or more drugs with complementary mechanisms of action, are gaining traction in the CACS drug market. These therapies aim to target multiple pathways involved in the pathogenesis of CACS, thereby providing more comprehensive symptom relief. The growing interest in personalized medicine and the development of novel combination regimens are expected to drive the growth of this segment. Clinical trials evaluating the efficacy of various combination therapies are underway, and positive results could significantly boost market uptake.

The "others" segment includes a variety of drug classes such as ghrelin mimetics, selective androgen receptor modulators (SARMs), and anti-inflammatory agents. Although these drugs currently hold a smaller market share, ongoing resear

In 2021, the number of cases of anorexia nervosa, along with the cases of bulimia recorded in Spain amounted to ******, up from ****** registered a year prior. The number of cases of these eating disorders increased by over *** percent in the country compared to 2011, when cases of anorexia nervosa and cases of bulimia reached ******.

Hospitalized dogs are predisposed to undernutrition, which can potentially affect outcome. This study evaluated the prevalence of undernutrition in hospitalized dogs (measured as loss of body condition score, BCS and body weight, BW) and studied the risk factors that affect nutritional status, and outcome (discharge or death). Data was collected prospectively during 9 months from 500 hospitalized dogs with a hospitalization length longer than 24 h in a veterinary teaching hospital in Spain. The BCS and BW changes were modeled using multiple linear regression and outcome was modeled using logistic regression. The risk factors studied were energy intake, hospitalization length, initial BW and BCS, age, sex, severity of clinical signs, department of admission, fasting or nutritional interventions, and the presence of anorexia, vomiting or diarrhea at admission. Most of the dogs (84.0%) consumed less than 25% of their energy requirements and only 3.4% of the dogs met these requirements. The majority of hospitalized dogs maintained their BCS (78.2%) and BW (77%) during hospitalization. Older patients (P = 0.040), higher initial BCS (P < 0.001), and vomiting at admission (P = 0.030) were associated with a decrease of BCS status during hospitalization. BCS was also decreased in patients with low energy intake, particularly in patients with hospitalization length longer than 3 days (P < 0.001). Both longer hospitalization length (P < 0.001) and vomiting at admission (P = 0.004) were also associated with a decrease in BW. Dogs that consumed their theoretical energy requirements [P < 0.001; Odds Ratio (OR) 0.95, 95% CI: 0.92 to 0.98], and had a higher initial BCS (P < 0.001; OR 0.39, 95% CI: 0.22 to 0.63) had a lower odds of dying. Anorexia at admission (P < 0.001; OR 5.67, 95% CI: 2.23 to 15.47) was associated with a higher risk of death. The results from this study support the finding that undernutrition is relatively common during hospitalization, with age, hospitalization length, decreased energy intake, and vomiting at admission as risk factors for undernutrition. Furthermore, an association was found between inadequate energy intake and death.

BackgroundLittle information has been published on the health status of pet chelonia. This study aimed to report on demography, commonly diagnosed disorders and mortality in chelonia under UK primary veterinary care in 2019.MethodsElectronic patient records on a random sample of chelonia in VetCompass during 2019 were reviewed to extract species, diagnosis and mortality data.ResultsOf 2,040 chelonia, 1,923 (94.26%) were recorded as tortoises, 74 (3.63%) terrapins and 43 (2.11%) turtles. Of the 811 (42.17%) tortoises with species information recorded, the most common species were Hermann’s tortoise (Testudo hermanni) (311, 38.35%), Horsfield’s tortoise (Testudo horsfieldii) (259, 31.94%) and Mediterranean spur-thighed tortoises (154, 18.99%). The most commonly diagnosed disorders were beak abnormalities (16.72%), overgrown nails (11.47%) and shell abnormalities (9.80%). The most common causes of death were disorder undiagnosed (44.55%), dog bite (5.45%) and anorexia (3.96%). Of 178 deaths with age recorded, the median age at death was 7.32 years (IQR 2.50-15.14).LimitationsRestricted lifelong records and clinical work-ups were a frequent limitation.ConclusionThis is the largest study of chelonia to date. It has highlighted that the most common disorders of chelonia are often linked to husbandry.

Baseline Characteristics of Crimean-Congo Hemorrhagic Fever Cases in Uganda, September 2022 –January 2023 (n = 13).

Die Interpersonelle Psychotherapie (IPT), ursprünglich zur Behandlung unipolarer depressiver Störungen entwickelt, wurde für die Behandlung verschiedener psychischer Störungen adaptiert, darunter die Essstörungen Bulimia nervosa, die Binge-Eating-Störung und die Anorexia nervosa. Die vorliegende systematische und praxisorientierte Übersicht stellt den aktuellen Forschungsstand zur IPT bei Essstörungen hinsichtlich der Wirksamkeit und Prädiktoren zusammen. Mehrere randomisierte klinische Studien legen nahe, dass die IPT bei der Bulimia nervosa zwar weniger schnell wirkt als die Kognitive Verhaltenstherapie (KVT), langfristig aber ebenso moderate bis gute Effekte mit ähnlicher Wirkungsweise erzielt. Für die Binge-Eating-Störung weist die IPT dieselbe gute kurz- und langfristige Wirksamkeit wie die KVT auf. Zur Behandlung der Anorexia nervosa legen Initialbefunde im Vergleich zu einem nicht spezifischen supportiven klinischen Management eine mäßige Wirksamkeit der IPT nahe, wobei langfristig Verbesserungen eintreten. Weiterentwicklungen in Konzept, Diagnostik und Vorgehen sowie eine größere wirksamkeits- und prozessbezogene Datenbasis können dazu beitragen, die Effektivität weiter zu optimieren sowie Indikation und Wirkungsweise der IPT für verschiedene Essstörungen zu spezifizieren